-
公开(公告)号：US11717523B2
公开(公告)日：2023-08-08
申请号：US17222873
申请日：2021-04-05
Applicant: G1 Therapeutics, Inc.
IPC: A61K31/527 , C07D487/14 , A61K45/06 , A61K31/519 , A61K31/5377 , A61P35/04 , A61P35/00 , A61K9/00 , A61K31/555 , A61K31/7048
CPC classification number: A61K31/527 , A61K9/0053 , A61K31/519 , A61K31/5377 , A61K31/555 , A61K31/7048 , A61K45/06 , A61P35/00 , A61P35/04 , C07D487/14
Abstract: This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.
-
公开(公告)号：US20220306644A1
公开(公告)日：2022-09-29
申请号：US17742315
申请日：2022-05-11
Applicant: G1 Therapeutics, Inc.
Inventor： Jay Copeland Strum
IPC: C07D487/20 , C07D487/04
Abstract: This invention is in the area of cell cycle inhibiting compounds for the treatment of disorders involving abnormal cellular proliferation, and include selective CDK2 inhibitors for medical therapy and their pharmaceutically acceptable salts and compositions.
-
3.发明申请公开(公告)号：US20220241275A1
公开(公告)日：2022-08-04
申请号：US17718052
申请日：2022-04-11
Applicant: G1 Therapeutics, Inc.
Inventor： Jay Copeland Strum , Chloe Whitworth , Daniel M. Freed
IPC: A61K31/498 , A61K31/519 , A61K45/06 , A61P35/00
Abstract: The present invention provides advantageous methods and compositions for treating a host having a cancer with dysregulation of the FGFR signaling pathway, which includes administering an effective amount of a selective CDK4/6 inhibitor described herein in combination or alternation with a fibroblast growth factor receptor inhibitor.
-
公开(公告)号：US20210395259A1
公开(公告)日：2021-12-23
申请号：US17153516
申请日：2021-01-20
Applicant: G1 Therapeutics, Inc.
Inventor： Francis X. Tavares , Jay Copeland Strum
IPC: C07D487/14 , C07D487/20 , A61K31/499 , A61K31/527 , C07D498/14 , C07D519/00
Abstract: Compounds of Formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
-
公开(公告)号：US20210299130A1
公开(公告)日：2021-09-30
申请号：US17222873
申请日：2021-04-05
Applicant: G1 Therapeutics, Inc.
IPC: A61K31/527 , C07D487/14 , A61K45/06 , A61K31/519 , A61K31/5377 , A61P35/04 , A61P35/00 , A61K9/00 , A61K31/555 , A61K31/7048
Abstract: This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.
-
Patent Agency Ranking
公开(公告)号：US20210213022A1
公开(公告)日：2021-07-15
申请号：US17181638
申请日：2021-02-22
Applicant: G1 Therapeutics, Inc.
Inventor： Jay Copeland Strum , John Emerson Bisi , Patrick Joseph Roberts , Francis X. Tavares
IPC: A61K31/527 , C07D487/14 , A61K45/06 , A61K31/519 , A61K31/5377 , A61P35/04 , A61P35/00 , A61K9/00 , A61K31/555 , A61K31/7048
Abstract: This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, improved treatment of select RB-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as highly selective and, in certain embodiments, short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.
-
7.发明申请公开(公告)号：US20210077498A1
公开(公告)日：2021-03-18
申请号：US17102311
申请日：2020-11-23
Applicant: G1 Therapeutics, Inc.
IPC: A61K31/527 , A61K45/06 , C07D487/20 , A61K38/18 , A61K38/19 , A61K38/20 , A61K31/202 , A61K31/702 , A61K31/519 , A61N5/10
Abstract: This invention is in the area of improved compounds and methods for transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC), from the damage associated with ionizing radiation (IR) exposure using selective radioprotectants.
-
公开(公告)号：US20200277300A1
公开(公告)日：2020-09-03
申请号：US15931330
申请日：2020-05-13
Applicant: G1 Therapeutics, Inc.
Inventor： Francis X. Tavares , Jay Copeland Strum
IPC: C07D487/14 , C07D487/20 , A61K31/499 , C07D498/14 , C07D519/00
Abstract: Compounds of Formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
-
公开(公告)号：US20200216406A1
公开(公告)日：2020-07-09
申请号：US16824290
申请日：2020-03-19
Applicant: G1 Therapeutics, Inc.
Inventor： Jay Copeland Strum
IPC: C07D333/64 , A61K31/55 , A61P35/00 , A61K31/397 , A61K31/4025 , A61K31/499 , A61K31/4535 , C07D409/12 , A61K31/381
Abstract: This invention is a benzothiophene estrogen receptor modulator or its pharmaceutically acceptable salt or a pharmaceutically acceptable composition thereof to treat an estrogen-related medical disorder.
-
公开(公告)号：US10696682B2
公开(公告)日：2020-06-30
申请号：US16226430
申请日：2018-12-19
Applicant: G1 Therapeutics, Inc.
Inventor： Francis X. Tavares , Jay Copeland Strum
IPC: A61K31/519 , C07D487/14 , C07D487/20 , A61K31/499 , C07D498/14 , C07D519/00
Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
-
-
-
-
-
-
-
-
-
Search Results
92
records
(took 0.021 seconds)
